XLV - Health Care Select Sector SPDR ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
86.75
-0.18 (-0.21%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close86.93
Open86.69
Bid0.00 x 0
Ask0.00 x 0
Day's range86.51 - 86.89
52-week range77.82 - 91.79
Volume4,447,829
Avg. volume7,984,498
Net assets15.05B
NAV83.42
PE ratio (TTM)N/A
Yield1.50%
YTD return1.67%
Beta (3y)0.98
Expense ratio (net)0.14%
Inception date1998-12-16
Trade prices are not sourced from all markets
  • 5 ETFs to Play in July
    Zacks13 days ago

    5 ETFs to Play in July

    Investors may tap these five ETFs for gains as President Trump aims the first shot in the trade war.

  • Markets up after strong jobs data offset trade war worries
    Yahoo Finance16 days ago

    Markets up after strong jobs data offset trade war worries

    Yahoo Finance's LIVE market coverage and analysis of stocks and bonds begins each day at 11:45 a.m. ET.

  • Barrons.com25 days ago

    Robust Outlook for Medical-Device Stocks

    Hambright initiated coverage of the sector with a bullish view, with Intuitive Surgical (ISRG), Boston Scientific (BSX), and Abbott Laboratories (ABT) as his Outperform-rated stocks. Then, of course, there are macro tailwinds, including an aging global population and expanding middle class and maturing medical care in emerging markets.

  • Barrons.comlast month

    High-Profile Health-Care Venture May Crimp Supply Chain, MCOs

    On Thursday, Amazon.com (AMZN), Berkshire Hathaway (BRK.B) and JPMorgan Chase (JPM) named Atul Gawande chief executive of their new health-care joint venture next month. Gawande has plenty of impressive credentials, as he practices general and endocrine surgery, teaches at Harvard Medical School, and is a bestselling author, among other accomplishments. Bernstein's Lance Wilkes weighs in on the appointment, writing that Gawande's appointment emphasizes the joint venture's enablement of change and disruption of the current healthcare system.

  • MarketWatchlast month

    American Medical Association urges Trump to stop separating immigrant children from parents

    Dr. James Madara, the chief executive of the American Medical Association, wrote to U.S. government officials on Tuesday urging them to stop a "zero tolerance" policy toward undocumented immigrants that so far has separated about 2,300 immigrant children from their parents. At a recent policy-making meeting of the U.S.'s foremost doctors group, delegates said the policy "will do great harm to children and their parents or caregivers, who felt compelled to make a dangerous and uncertain journey because of safety concerns in their own countries," Madara wrote in the letter, which was made public early Wednesday. It is well known that childhood trauma and adverse childhood experiences created by inhumane treatment often create negative health impacts that can last an individual's entire lifespan." The Trump administration announced the zero-tolerance policy in early May and views separating children from their families as a deterrent to illegal migrants, according to a report.

  • 5 ETF Ways to Trade 6-Year High U.S. Inflation
    Zackslast month

    5 ETF Ways to Trade 6-Year High U.S. Inflation

    Why these ETF areas can gain in an inflationary environment.

  • MarketWatchlast month

    These 7 states are most at risk from rising health-care costs

    High and growing health-care costs are a problem for everyone — but especially so for state and local governments. Related: Doctor’s offices are a hot investment — what does that mean for profit vs. patient care?FitchU.S. state and local governments spent 30.7% of their budgets on health care and social services in 2015, an increase from 27.6% in 2005.

  • Trade tensions rise, markets slip
    Yahoo Financelast month

    Trade tensions rise, markets slip

    Midday Movers paste ‘Yahoo Finance's LIVE market coverage and analysis of stocks and bonds begins each day at 11:45 a.m. ET.

  • Pharmaceutical ETFs and Their Performances in May
    Market Realist2 months ago

    Pharmaceutical ETFs and Their Performances in May

    Pharmaceutical ETFs are securities that are publicly traded on the stock market and designed for investors wanting to diversify their investments in the pharmaceutical sector.

  • For investors looking for a summer fling, one sector could fit the bill
    CNBC2 months ago

    For investors looking for a summer fling, one sector could fit the bill

    Health care has been the best-performing sector between June and August since 1990, according to a new Oppenheimer note. But if the sector rallied this year, not all names in the group will participate, says the firm’s top technician.

  • Biotech Sector Continue to Dazzle Despite Market Distress
    Market Realist2 months ago

    Biotech Sector Continue to Dazzle Despite Market Distress

    Biotech stocks—with their binary outcomes and potential FDA approvals or denials—should whip around, pending various outcomes. It doesn’t help that President Trump (seemingly at random) decides periodically that we all pay too much for drugs. For biotech stocks to work on the long side investors’ risk appetite would have to take off or a major approval could drive the stocks up.

  • Incyte’s Revenue Trend in Q1 2018
    Market Realist2 months ago

    Incyte’s Revenue Trend in Q1 2018

    Incyte’s (INCY) consolidated revenue rose to $328.3 million in Q1 2018 compared to $384.1 million in Q1 2017. In Q1 2018, the company reported net revenue of -$2.6 million compared to $29.1 million in Q1 2017.

  • Analyzing Tepper’s Top Investment Sectors
    Market Realist2 months ago

    Analyzing Tepper’s Top Investment Sectors

    Previously, we discussed billionaire investor David Tepper’s largest holdings and top buys and sells in the first quarter. In this part, we’ll look at Tepper’s top investment sectors based on his Appaloosa Management holdings.

  • MarketWatch2 months ago

    President Trump’s big drug price speech boosts pharma stocks

    After weeks of build-up, drug industry watchers began to have real concerns about President Donald Trump’s big drug price speech on Friday. Many of the changes that were mentioned on Friday had been raised before by his administration, including drug price negotiation for certain government programs. Other proposals seemed unlikely to significantly bring down drug prices in the near-term, which Trump described as a goal of the plan.

  • Trump lets drug companies off the hook
    Yahoo Finance2 months ago

    Trump lets drug companies off the hook

    After several delays, President Trump unveiled a plan to lower drug prices. Don't bank on it just yet.

  • MarketWatch2 months ago

    Drug stocks slip, then swing back even higher after Trump unveils drug cost cutting plan

    Healthcare stocks dipped after President Donald Trump started presenting his plan to cut prescription drug costs, then bounced sharply to trade even higher than pre-speech levels. The SPDR Health Care Select Sector ETF was up about 0.5% before Trump's speech began, then slid to be down 0.1% swinging higher to be up 1.1% at a new intraday high. Some changes to policy announced by Trump and Health and Human Services Secretary Alex Azar included drug price negotiation by government programs, an end to the "gag rule" on pharmacists--who cannot disclose if drug products can be bought for cheaper without using a health plan -- and disclosure of drugs' list prices pharmaceutical advertisements.

  • Health-care stocks whipsaw as Trump unveils plan to lower prescription drug prices
    CNBC2 months ago

    Health-care stocks whipsaw as Trump unveils plan to lower prescription drug prices

    Health care stocks whipsawed on Friday as President Donald Trump unveiled his long-awaited plan to lower prescription drug prices, dubbed "American Patients First."

  • What Were the Hiring and Firing Trends in March?
    Market Realist2 months ago

    What Were the Hiring and Firing Trends in March?

    The “Job Openings and Labor Turnover Survey” (or JOLTS) data for March was reported on May 8 and contains key information about job openings and total separations. The total number of separations include layoffs, retirements, and voluntary quits. As per the latest JOLTS report, the total separations for March came in at 5.3 million at a rate of 3.6% of the total workforce, an increase from the February reading of 5.2 million and 3.5%, respectively.

  • FDA Approves JNJ’s Darzalex in Combination with VMP
    Market Realist2 months ago

    FDA Approves JNJ’s Darzalex in Combination with VMP

    Johnson & Johnson’s (JNJ) Darzalex injection is a CD-38 surface protein–directed antibody approved for the treatment of multiple myeloma. Today, JNJ announced that the US Food & Drug Administration (or FDA) approved Darzalex in combination with other drugs for the treatment of multiple myeloma, marking the fifth indication for which Darzalex has FDA approval.

  • Analyzing Merck’s Revenue in 1Q18
    Market Realist2 months ago

    Analyzing Merck’s Revenue in 1Q18

    Merck (MRK), one of the largest pharmaceutical companies worldwide, is classified into four business segments: Human Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company reported its 1Q18 results on May 1. During the quarter, Merck surpassed analysts’ EPS (earnings per share) estimate of $1, but missed their revenue estimate of $10.1 billion, reporting EPS of $1.05 on revenue of $10.0 billion.

  • Which Sector Posted Major Job Gains in April?
    Market Realist3 months ago

    Which Sector Posted Major Job Gains in April?

    The ADP March employment report was published on May 2. The report offered deeper insight into employment trends across different sectors in the US employment market. ADP and Moody’s Analytics prepared the monthly report.

  • Mounting Evidence of Inflation Firming Up
    Market Realist3 months ago

    Mounting Evidence of Inflation Firming Up

    The U.S. Commerce Department reported retail sales fell in February for the third month in a row, while the University of Michigan Consumer Sentiment Index4 jumped to a 14-year high and the Conference Board Consumer Confidence Index5 hovers near 17-year highs. This suggests that while times are good for most people, they have little desire to spend more in an economic expansion that is one of the longest on record. Households may save their gains from the Trump tax cuts, rather than spend in the economy, as the Commerce Department reports the savings rate ticked higher in February.

  • Merck & Co.’s 1Q18 Earnings: Revenues up 6%
    Market Realist3 months ago

    Merck & Co.’s 1Q18 Earnings: Revenues up 6%

    Headquartered in New Jersey, Merck & Co. (MRK) is one of the largest pharmaceutical companies worldwide. Its business is classified into four business segments: Human Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck & Co. beat Wall Street analysts’ estimates for earnings per share (or EPS) today but missed analysts’ estimates for revenues. It reported EPS of $1.05 on revenues of $10.0 billion for 1Q18, compared to estimates of EPS of $1.00 on revenues of $10.1 billion.

  • Jim Chanos: ‘Winter Is Coming to the US Health Care System’
    Market Realist3 months ago

    Jim Chanos: ‘Winter Is Coming to the US Health Care System’

    Famed short seller Jim Chanos said in a recent interview, “winter is coming to the US health care system.” He has a bearish view on the healthcare sector and disclosed that he has a short position in Envision Healthcare (EVHC). EVHC stock price fell 2.2% on April 26 after Jim Chanos’s announcement about his short position in the stock.

  • Merck & Co.’s 1Q18 Earnings: Analysts’ Estimates
    Market Realist3 months ago

    Merck & Co.’s 1Q18 Earnings: Analysts’ Estimates

    Merck & Co. (MRK) is set to release its 1Q18 earnings tomorrow. Wall Street analysts expect earnings per share (or EPS) of $1.00 on revenues of ~$10.1 billion for 1Q18.